Autonomix Medical Inc (AMIX) Stock Price, Quote & News

Company Profile

Autonomix Medical, Inc., a development stage medical device company, focuses on advancing technologies for sensing and treating disorders relating to the peripheral nervous system. The company's technology platform includes a catheter-based microchip-enabled sensing array to detect and differentiate peripheral neural signals. It develops technology for patients with pancreatic cancer and addresses indications for chronic pain management, hypertension, cardiovascular, and other nerve-related diso...

Industry: Medical Devices

Sector: Healthcare

Phone: 713 588 6150

Website: autonomix.com

Address:

21 Waterway Avenue, Suite 300, The Woodlands, United States

coolmate25 Mar. 17 at 8:01 PM

$AMIX Some low life's fcked up in a very last minute in order to get some fat pants for their mom 😆.

0 · Reply

coolmate25 Mar. 17 at 5:04 PM

$AMIX Why is 0.45 a buffer zone from the last 3 trading days ? Buy Hold and let's cross the boundary.

1 · Reply

DarkSonar Mar. 16 at 11:01 PM

$AMIX This is looking like is setting up… Monitoring. 🔬

0 · Reply

coolmate25 Mar. 16 at 2:36 PM

$AMIX Great !

0 · Reply

Ron_Burn Mar. 16 at 3:54 AM

$AMIX buy buy buy

0 · Reply

dwhall5056 Mar. 14 at 11:03 AM

$AMIX Autonomix seems to be checking all the boxes for building its product. Why not get on board and ride the stock up. Some may call, what they are doing, Amazing. https://www.autonomix.com/

0 · Reply

coolmate25 Mar. 13 at 4:47 PM

$AMIX Come on guys ! All the way to $0.45 then grounded to $0.42 in no time . I mean seriously? Who are these fckn low life parasites? My average is $0.45 too but I don't wanna sell since I'm holding a huge huge pile of this sh-t and I don't wanna mess it up for other professionals. Big newses in pipeline soon .

0 · Reply

VinWeezel Mar. 13 at 3:41 PM

$AMIX

0 · Reply

sirjohann Mar. 13 at 9:54 AM

$AMIX wtf is wrong with the stock?????? it got delisted???

2 · Reply

coolmate25 Mar. 12 at 1:48 PM

$AMIX Both Codx and Amix needs FDA approval to hit all time high and they are close to this milestone.

1 · Reply

Autonomix Medical to Present at LSI USA '26

Mar 5, 2026, 8:45 AM EST - 12 days ago

Autonomix Medical Selected for Best Innovation Competition at CRT 2026

Mar 4, 2026, 8:40 AM EST - 13 days ago

Autonomix Medical Selected as Top Abstract at CRT 2026 and Selected for Podium Presentation of Clinical Feasibility and Outcomes of Novel Technique for Transvascular Peripheral RF Nerve Neurolysis

Feb 25, 2026, 8:30 AM EST - 20 days ago

Autonomix Medical Announces Release of New CEO Corner Segment Highlighting Publication Strategy and Scientific Validation

Feb 19, 2026, 8:30 AM EST - 26 days ago

Autonomix Medical Selected to Present New Long-Term Pain Mitigation Data in Pancreatic Cancer at SSO 2026 Annual Meeting in Podium Presentation

Jan 9, 2026, 8:45 AM EST - 2 months ago

Autonomix Showcases Compelling PoC Study Clinical Data Showing Rapid and Durable Pain Relief Across All Disease Stages of Pancreatic Cancer at the 2026 ASCO Gastrointestinal (GI) Cancers Symposium

Dec 23, 2025, 8:45 AM EST - 3 months ago

Autonomix Medical, Inc. (NASDAQ: AMIX) Highlights Expanding IP Portfolio and Multi-Indication Platform Strategy in Virtual Investor CEO Connect Segment

Dec 18, 2025, 8:30 AM EST - 3 months ago

Autonomix Medical, Inc. Announces Abstract Selected for Poster Presentation at the 2026 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium

Nov 26, 2025, 8:45 AM EST - 3 months ago

Autonomix Medical, Inc. (NASDAQ: AMIX) Announces Release of the Next CEO Corner Segment Highlighting Continued Execution and Strategic Growth

Oct 24, 2025, 9:00 AM EDT - 5 months ago

Autonomix Medical, Inc. Featured in Two Innovation in Interventional Cardiology Podium Presentations at the Transcatheter Cardiovascular Therapeutics® (TCT®) Annual Scientific Conference

Oct 16, 2025, 9:15 AM EDT - 5 months ago

Autonomix Medical, Inc. to Highlight Innovative Nerve-Sensing and Ablation Platform at the 2025 Maxim Growth Summit

Oct 9, 2025, 8:45 AM EDT - 5 months ago

Autonomix Medical, Inc. Granted U.S. Patent on Platform Technology Enabling Precision Nerve-Targeted Therapies in Cardiology

Oct 2, 2025, 8:45 AM EDT - 5 months ago

Autonomix Medical, Inc. Announces Release of the Next CEO Corner Segment

Sep 29, 2025, 9:15 AM EDT - 6 months ago

Autonomix Medical, Inc. Initiates Good Laboratory Practice (GLP) Study for Sensing and RF Ablation System

Sep 4, 2025, 9:00 AM EDT - 6 months ago

Autonomix Medical, Inc. (NASDAQ: AMIX) Participates in Virtual Investor “What This Means” Segment

Sep 3, 2025, 8:30 AM EDT - 6 months ago

Autonomix Medical, Inc. Demonstrates Sustained Pain Reduction, Quality of Life Gains and 100% Zero Opioid Use in Longer-Term Post Hoc Analysis from PoC 1 Study

Sep 2, 2025, 8:30 AM EDT - 7 months ago

Autonomix Medical, Inc. to Present at H.C. Wainwright 27th Annual Global Investment Conference

Aug 18, 2025, 9:15 AM EDT - 7 months ago

Autonomix Medical, Inc. to Participate in Virtual Investor Webinar Hosted by Ladenburg Thalmann & Co. Inc.

Aug 15, 2025, 9:00 AM EDT - 7 months ago

Autonomix Medical, Inc. to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech

Aug 14, 2025, 8:30 AM EDT - 7 months ago

Autonomix Medical, Inc. Finalizes Design Review of First-Ever Intravascular Nerve Sensing Catheter in Key Step Toward U.S. Clinical Studies

Jul 22, 2025, 8:45 AM EDT - 8 months ago

Autonomix Medical, Inc. Participates in the Virtual Investor “What's Your Story” Summer Spotlight On-Demand Conference

Jul 21, 2025, 8:45 AM EDT - 8 months ago

Autonomix Medical, Inc. Granted New U.S. Patent to Advance Minimally Invasive, Nerve-Focused Treatments Across High-Need Indications

Jun 30, 2025, 8:30 AM EDT - 9 months ago

Autonomix Medical, Inc. Treats First Patient in Follow-On Market Expansion Phase (“PoC 2”) of Proof-of-Concept Human Clinical Study

Jun 27, 2025, 8:00 AM EDT - 9 months ago

Autonomix Medical, Inc. Granted New U.S. Patent for Innovative Catheter-Based Platform Technology

Jun 5, 2025, 8:45 AM EDT - 10 months ago

Autonomix Medical, Inc. Granted Approval to Expand Proof-of-Concept Human Clinical Study, Doubling Potential Addressable Market Beyond Pancreatic Cancer Pain

May 15, 2025, 8:30 AM EDT - 10 months ago

Autonomix Medical, Inc. Granted Key U.S. Patent for Innovative Catheter-Based Platform Technology

May 14, 2025, 9:20 AM EDT - 10 months ago

Autonomix CEO Brad Hauser to Present at Virtual Investor's Closing Bell Event

May 13, 2025, 9:20 AM EDT - 11 months ago

Brad Hauser, CEO of Autonomix Medical, Inc. Outlines Follow-On Expansion Study Expected to Begin in Q2 2025, Potentially Doubling Addressable Market

May 5, 2025, 8:30 AM EDT - 11 months ago

Autonomix Highlights Compelling Patient Testimonial Showing Rapid Pain Relief from First-in-Human Proof-of-Concept Trial in Pancreatic Cancer Pain

May 1, 2025, 9:25 AM EDT - 11 months ago

Autonomix Medical, Inc. (NASDAQ: AMIX) Participates in Virtual Investor “What This Means” Segment Highlighting Key Learnings from First-In-Human Trial and Extension into Visceral Cancer Pain

Apr 30, 2025, 8:15 AM EDT - 11 months ago

Autonomix Medical, Inc. Reports Positive Outcomes in Initial Phase of First-in-Human Proof-of-Concept Trial in Pancreatic Cancer Pain and Initiates Market Expansion Study for Visceral Cancer Pain

Apr 24, 2025, 8:30 AM EDT - 11 months ago

Autonomix Medical, Inc. Technology and Early Proof-of-Concept Study Results to be Featured in Poster Presentation at the World-Leading Course in Interventional Cardiovascular Medicine, EuroPCR

Apr 17, 2025, 5:00 PM EDT - 11 months ago

Autonomix Medical, Inc. Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Apr 16, 2025, 8:30 AM EDT - 11 months ago

Autonomix Medical, Inc. Granted New European Patent for Proprietary Catheter-Based Technology

Apr 8, 2025, 8:15 AM EDT - 1 year ago

Autonomix Medical, Inc. Engages Leading Medical Experts to Guide U.S. Clinical and Regulatory Path in Pancreatic Cancer Pain

Apr 3, 2025, 8:30 AM EDT - 1 year ago

Autonomix Medical, Inc. to Highlight Technology and Early Proof-of-Concept Study Results in a Poster Presentation at the 2025 European Conference on Interventional Oncology (ECIO)

Mar 20, 2025, 8:30 AM EDT - 1 year ago

Autonomix Medical, Inc. Granted U.S. Patent Covering Sensing Data Collection and Processing with Company's Proprietary Catheter-Based Technology

Mar 14, 2025, 8:30 AM EDT - 1 year ago

Autonomix Medical, Inc. Advances Toward U.S. Clinical Trials in 2025 with Completed Integration of Apex 6 Generator for Transvascular Ablation

Feb 20, 2025, 8:30 AM EST - 1 year ago

Autonomix Medical, Inc. Selected for Podium Presentation at the 2025 CRT Annual Meeting

Feb 13, 2025, 8:00 AM EST - 1 year ago

Autonomix Medical, Inc. Reports Third Quarter Fiscal Year 2025 Financial Results and Provides a Corporate Update

Jan 24, 2025, 8:45 AM EST - 1 year ago

Autonomix Medical, Inc. (NASDAQ: AMIX) Announces Release of the Next CEO Corner Segment

Jan 17, 2025, 8:00 AM EST - 1 year ago

Autonomix Medical, Inc. Finalizes Design of ASIC Microchip for Sensing Technology Catheter for Use in Humans, Continuing Progress Toward a U.S. Pivotal Trial in 2025

Jan 15, 2025, 8:30 AM EST - 1 year ago

Autonomix Medical, Inc. (NASDAQ: AMIX) to Participate in the Virtual Investor Closing Bell Series

Jan 13, 2025, 8:30 AM EST - 1 year ago

Autonomix Medical, Inc. Announces Abstract Highlighting Preliminary Positive Clinical Results Accepted at The Society of Interventional Oncology (SIO) 2025 Annual Scientific Meeting

Dec 30, 2024, 8:30 AM EST - 1 year ago

Autonomix Medical, Inc. Announces U.S. Patent Granted Covering the Treatment of Cancerous Tumors and Cancer Related Pain with Company's Proprietary Catheter-Based Technology

Dec 5, 2024, 8:30 AM EST - 1 year ago

Autonomix Medical, Inc. Achieves Design Lock for RF Ablation Catheter Following Successful Completion of Animal Testing, Continuing Progress Toward a U.S. Pivotal Trial in 2025

Nov 25, 2024, 4:00 PM EST - 1 year ago

Autonomix Medical, Inc. Announces Closing of $10.0 Million Underwritten Public Offering Including Partial Exercise of Over-Allotment Option

Nov 22, 2024, 9:15 AM EST - 1 year ago

Autonomix Medical, Inc. Announces Pricing of $9.0 Million Underwritten Public Offering

Nov 11, 2024, 8:00 AM EST - 1 year ago

Autonomix Medical, Inc. Reports Second Quarter Fiscal Year 2025 Financial Results and Provides a Corporate Update

Oct 30, 2024, 8:30 AM EDT - 1 year ago

Autonomix Medical, Inc.'s Dr. Robert Schwartz Discusses What Positive 4-6 Week Follow-Up Data Means from Lead-In Patients in Ongoing Human Clinical Trial

coolmate25 Mar. 17 at 8:01 PM

$AMIX Some low life's fcked up in a very last minute in order to get some fat pants for their mom 😆.

0 · Reply

coolmate25 Mar. 17 at 5:04 PM

$AMIX Why is 0.45 a buffer zone from the last 3 trading days ? Buy Hold and let's cross the boundary.

1 · Reply

DarkSonar Mar. 16 at 11:01 PM

$AMIX This is looking like is setting up… Monitoring. 🔬

0 · Reply

coolmate25 Mar. 16 at 2:36 PM

$AMIX Great !

0 · Reply

Ron_Burn Mar. 16 at 3:54 AM

$AMIX buy buy buy

0 · Reply

dwhall5056 Mar. 14 at 11:03 AM

$AMIX Autonomix seems to be checking all the boxes for building its product. Why not get on board and ride the stock up. Some may call, what they are doing, Amazing. https://www.autonomix.com/

0 · Reply

coolmate25 Mar. 13 at 4:47 PM

0 · Reply

VinWeezel Mar. 13 at 3:41 PM

$AMIX

0 · Reply

sirjohann Mar. 13 at 9:54 AM

$AMIX wtf is wrong with the stock?????? it got delisted???

2 · Reply

coolmate25 Mar. 12 at 1:48 PM

$AMIX Both Codx and Amix needs FDA approval to hit all time high and they are close to this milestone.

1 · Reply

dwhall5056 Mar. 11 at 8:28 PM

$AMIX Sure would like to know what the JTC team is doing to represent the company to the public and make it visible. https://ir.autonomix.com/ir-contacts/

0 · Reply

dwhall5056 Mar. 11 at 1:38 PM

$AMIX Brad Hauser, President and Chief Executive Officer of Autonomix will present at LSI USA ’26 on Tuesday, March 17, 2026 at 9:15 AM PT. ... https://ir.autonomix.com/autonomix-medical-to-present-at-lsi-usa-26/

0 · Reply

coolmate25 Mar. 11 at 12:18 PM

$AMIX Autonomix Medical plans to submit a De Novo application for FDA approval this year. This follows their planned initiation of pivotal U.S. clinical trials in 2025 and the reporting of top-line data from these trials expected in 2026. The company is targeting FDA clearance for its RF ablation device by 2027, according to a Nasdaq article.

0 · Reply

coolmate25 Mar. 10 at 7:18 PM

$AMIX Just bought more , I don't know who the fk is selling ? Other than a cheap souls looking for a mcmeal .

1 · Reply

PatentGrants Mar. 9 at 7:57 PM

$AMIX Autonomix Medical has received a Notice of Allowance for a US patent titled "DEVICES, SYSTEMS, AND METHODS FOR DIAGNOSIS AND TREATMENT OF OVERACTIVE BLADDER". https://patentcenter.uspto.gov/applications/18079361/ifw/docs

1 · Reply

coolmate25 Mar. 9 at 7:09 PM

$AMIX lots of loosers ! Professionals have been holding for 2 years while some are done in as little as month . All of this company's clinical trials are successful, just waiting for that stupid fda approval and this will hit all time high.

1 · Reply

sirjohann Mar. 9 at 1:22 PM

$AMIX i don’t want to sound desperate or anything but im about to take my lost and move, im smelling aggressive reverse split at any moment

0 · Reply

BigTimePennyStocks Mar. 8 at 5:07 PM

Small-Caps with Catalysts this week: 👇👇 ( $PHIO, $AMIX, $SGN, $TIVC, $PAPL, etc...) #NASDAQ #NYSE

1 · Reply

RISE07 Mar. 6 at 3:17 PM

$AMIX

0 · Reply

GaryBx105 Mar. 6 at 3:11 PM

$AMIX very narrow BB. history of spiking before offering. first class technology.

0 · Reply

coolmate25 Mar. 5 at 9:04 PM

$AMIX Good day overall minus cheap day traders.

0 · Reply

dwhall5056 Mar. 5 at 2:00 PM

$AMIX link for Autonomix Medical Selected for Best Innovation Competition at CRT 2026 ... https://ir.autonomix.com/autonomix-medical-selected-for-best-innovation-competition-at-crt-2026/

0 · Reply

Market Cap	2.94M
Revenue (ttm)	0.00
Net Income (ttm)	-11.41M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	82,900
Avg Vol	1,181,660
Day's Range	N/A - N/A
Shares Out	6.91M
Stochastic %K	76%
Beta	-2.80
Analysts	Strong Sell
Price Target	$2.00